2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Pathogenesis, CHIP, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3613 Peripheral blood T-cell receptor gamma clonality assay is a reliable predictor of bone marrow status: Findings from 75 paired samples

Xi Cao, MD, Huan-You Wang, MD, PhD2, Jennifer Chousal, MD, PhD3, Wei Song, MD, PhD4, Erin Reid, MD5
1 University of California, San Diego, La Jolla, California, United States
2 University of California, San Diego, La Jolla, California, United States
3 University of California, San Diego, La Jolla, California, United States
4 University of California, San Diego, La Jolla, California, United States
5 University of California, San Diego, La Jolla, California, United States

Background: T-cell receptor gamma (TCRG) gene rearrangement is the most commonly performed TCRG assay on peripheral blood (PB) and bone marrow (BM), but the frequency of PB-BM discordance and its significance are poorly characterized. We evaluated paired PB-BM TCRG results from 75 patients, emphasizing clinical and flow-cytometric features of discordant cases. 

Methods: We retrospectively identified 75 patients with paired PB-BM TCRG testing at our institution from 2013 to June 2026. Pairs with intervening antineoplastic therapy or hematopoietic stem cell transplantation were excluded. Pairs tested within 30 days (n=52) and all eligible pairs (n=75; interval, 0-888 days) comprised the primary and expanded cohorts, respectively. TCRG rearrangement testing was performed by PCR using BIOMED-2 primers and interpreted as positive or negative. BM T-cell immunophenotype by 10-color flow cytometry (FCM) was classified as negative, nonspecific (minor variation without discrete aberrancy), suspicious (atypical population of uncertain significance), or positive (definite aberrant population). Clinical indications were categorized as known T-cell lymphoma (TCL)/lymphoproliferative disorder (T-LPD), suspected TCL/T-LPD, broad evaluation to exclude a T-cell process, or other/unclear. Percent agreement, Cohen kappa, exact McNemar, Fisher exact, and Cochran-Armitage tests assessed agreement, positivity, indication/interval associations, and BM FCM trends, respectively. Discordant cases underwent clinical and FCM review. 

Results: In the primary cohort (n=52), 19 pairs were PB+/BM+, 25 PB−/BM−, 7 PB+/BM−, and 1 PB−/BM+, yielding 85% (44/52) agreement (kappa=0.69) and 15% (8/52) discordance. PB positivity was numerically higher than BM positivity [50.0% (26/52) vs 38.5% (20/52); exact McNemar P=.070]. In the expanded cohort (n=75), 28 pairs were PB+/BM+, 34 PB−/BM−, 11 PB+/BM−, and 2 PB−/BM+, yielding 83% (62/75) agreement (kappa=0.66) and 17% (13/75) discordance. PB positivity was higher than BM positivity [52.0% (39/75) vs 40.0% (30/75); P=.022]. Discordance did not differ between intervals ≤30 and >30 days (15% vs 22%; P=.52). 

Clinical indications were known TCL/T-LPD in 13, suspected TCL/T-LPD in 24, broad exclusionary evaluation in 37, and other/unclear in 1; indication was not associated with discordance (P=.93). 

The 13 discordant patients, including 8 from the primary cohort, had a median age of 66 (range, 29-82) and a median absolute lymphocyte count of 1.0 × 10^9/L (range, 0.1-4.9). Two had known TCL at testing: one had PTCL (PB+/BM−) without BM involvement, and one had mycosis fungoides (MF; PB−/BM+) with BM-only involvement. Of the remaining 11, 5 underwent targeted evaluation for suspected T-LPD and 6 broad evaluations. All 5 suspected cases were PB+/BM−: 4 had lymphocytosis and 1 had an incidental abnormal T-cell finding during B-cell lymphoma follow-up. Five of the 6 broad-evaluation cases were PB+/BM−; indications included suspected pure red cell aplasia, hemophagocytic lymphohistiocytosis, autoimmune- or infection-associated cytopenia, and 2 unexplained cytopenias. One patient was subsequently diagnosed with T-LGLL. 

BM FCM was available in 12 of 13 discordant cases. Among PB+/BM− cases with BM FCM, 7 of 10 had negative/nonspecific findings and 3 suspicious/positive findings; both PB−/BM+ cases had suspicious BM FCM. Across all 73 patients with BM FCM, BM TCRG positivity increased stepwise across negative, nonspecific, suspicious, and positive categories: 19%, 37%, 67%, and 85%, respectively (P<.001). 

Conclusions: 1) PB TCRG testing is minimally invasive and showed 83–85% agreement with BM, supporting it as a reliable predictor of BM TCRG status in most patients; 2) PB+/BM− discordance occurred in 13%–15%. These findings may reflect compartment-specific disease rather than assay error: the patient with PTCL had no BM involvement, and a subsequently diagnosed T-LGLL case had PB positivity but negative BM TCRG testing. Because TCRG clonality is not malignancy-specific, PB+/BM− results cannot be classified as reactive or malignant without clinicopathologic correlation. Among patients without an established TCL/T-LPD, positive PB TCRG clonality alone could represent reactive expansion or T-cell clones of uncertain significance; 3) PB−/BM+ cases were rare (2%–3%): one had BM involvement by MF, whereas a separate patient underwent a broad evaluation to rule out T-LPD and was non-diagnostic by morphological evaluation. 

Xi Cao, MD: No relevant conflicts of interest to declare.